Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX +8.33% EV-to-EBIT is -2.23 as of Jul. 23, 2026. The stock has 4 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 961537.5% on this metric.
The historical rank and industry rank for Imagion Biosystems's EV-to-EBIT or its related term are showing as below:
ASX:IBX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -25.55 Med: -1 Max: 1.21
Current: -2.24
During the past 9 years, the highest EV-to-EBIT of Imagion Biosystems was 1.21. The lowest was -25.55. And the median was -1.00.
ASX:IBX's EV-to-EBIT is ranked worse than 100% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.79
vs ASX:IBX: -2.24
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Imagion Biosystems's Enterprise Value for the quarter that ended in Dec. 2025 was A$12.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems EV-to-EBIT Related Terms
Imagion Biosystems EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's EV-to-EBIT falls into.
Imagion Biosystems's current Enterprise Value is A$7.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a EV-to-EBIT of -2.23 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' EV-to-EBIT too high?
Imagion Biosystems' current EV-to-EBIT is -2.23. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 104 companies for EV-to-EBIT. This places Imagion Biosystems in the lower half of its industry. The industry median EV-to-EBIT is 22.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.79, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current EV-to-EBIT is -2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 98.8% below its estimated fair value. The current EV-to-EBIT is -2.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current EV-to-EBIT is -2.23 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
